Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.84 |
| ▸ | LMNA | P02545 | 1/20 | 0.84 |
| ▸ | PRKCA | P17252 | 4/20 | 0.72 |
| ▸ | PRKCE | Q02156 | 2/20 | 0.72 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.72 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.72 |
| ▸ | LPAR3 | Q9UBY5 | 7/20 | 0.68 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.68 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.68 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.66 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13997507 | 1.00 | ALDH1A1 (0.84) | ALDH1A1LMNAPRKCAPRKCEPRKCQ | |
| SCHEMBL11782897 | 1.00 | ALDH1A1 (0.84) | ALDH1A1LMNAPRKCAPRKCEPRKCQ | |
| SCHEMBL4862128 | 1.00 | ALDH1A1 (0.84) | ALDH1A1LMNAPRKCAPRKCEPRKCQ | |
| SCHEMBL18010946 | 1.00 | ALDH1A1 (0.84) | ALDH1A1LMNAPRKCAPRKCEPRKCQ | |
| SCHEMBL345928 | 1.00 | ALDH1A1 (0.84) | ALDH1A1LMNAPRKCAPRKCEPRKCQ | |
| SCHEMBL21472154 | 1.00 | ALDH1A1 (0.84) | ALDH1A1LMNAPRKCAPRKCEPRKCQ | |
| SCHEMBL25272152 | 1.00 | ALDH1A1 (0.84) | ALDH1A1LMNAPRKCAPRKCEPRKCQ | |
| SCHEMBL19285724 | 1.00 | ALDH1A1 (0.84) | ALDH1A1LMNAPRKCAPRKCEPRKCQ | |
| SCHEMBL21409342 | 1.00 | ALDH1A1 (0.84) | ALDH1A1LMNAPRKCAPRKCEPRKCQ | |
| SCHEMBL18613715 | 1.00 | ALDH1A1 (0.84) | ALDH1A1LMNAPRKCAPRKCEPRKCQ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023123986-A1 | UTIDELONE LIPOSOME COMPOSITION, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 成都华昊中天药业有限公司 | 2023-07-06 | — | — | WO | claimed |
| CN-118251497-A | Lipid compositions comprising peptide-lipid conjugates | 阿克丘勒斯治疗公司 | 2024-06-25 | — | — | CN | disclosed |
| CN-118201639-A | Peptide-lipid conjugates | 阿克丘勒斯治疗公司 | 2024-06-14 | — | — | CN | disclosed |
| EP-4333898-A2 | PEPTIDE-LIPID CONJUGATES | Arcturus Therapeutics, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| EP-4334455-A1 | LIPID COMPOSITIONS COMPRISING PEPTIDE-LIPID CONJUGATES | Arcturus Therapeutics, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| US-20220378702-A1 | PEPTIDE-LIPID CONJUGATES | ARCTURUS THERAPEUTICS, INC. | 2022-12-01 | — | — | US | disclosed |
| US-20220370624-A1 | LIPID COMPOSITIONS COMPRISING PEPTIDE-LIPID CONJUGATES | ARCTURUS THERAPEUTICS, INC. | 2022-11-24 | — | — | US | disclosed |
| WO-2022235972-A1 | LIPID COMPOSITIONS COMPRISING PEPTIDE-LIPID CONJUGATES | ARCTURUS THERAPEUTICS, INC. (US) | 2022-11-10 | — | — | WO | disclosed |
| WO-2022235923-A2 | PEPTIDE-LIPID CONJUGATES | ARCTURUS THERAPEUTICS, INC. (US) | 2022-11-10 | — | — | WO | disclosed |
| CN-110997693-A | Tau aggregation inhibitors | 阿德克斯公司 | 2020-04-10 | — | — | CN | disclosed |
| US-8192753-B2 | pH-sensitive cationic lipids, and liposomes and nanocapsules containing the same | MARINA BIOTECH, INC. (US) | 2012-06-05 | — | — | US | disclosed |
| US-8193246-B2 | Lipids and lipid assemblies comprising transfection enhancer elements | MARINA BIOTECH, INC. (US) | 2012-06-05 | — | — | US | disclosed |
| US-20120021042-A1 | Efficient Method For Loading Amphoteric Liposomes With Nucleic Acid Active Substances | MARINA BIOTECH, INC. | 2012-01-26 | — | — | US | disclosed |
| US-20090220584-A1 | Amphoteric Liposome Formulation | BIONTECH PROTEIN THERAPEUTICS GMBH (DE) | 2009-09-03 | — | — | US | disclosed |
| US-20080306153-A1 | Lipids and lipid assemblies comprising transfection enhancer elements | CEQUENT PHARMACEUTICALS, INC. | 2008-12-11 | — | — | US | disclosed |
| US-20080145413-A1 | Lipids and lipid assemblies comprising transfection enhancer elements | MARINA BIOTECH, INC. | 2008-06-19 | — | — | US | disclosed |
| US-20060002991-A1 | Ph-sensitive cationic lipids, and liposomes and nanocapsules containing the same | NOVOSOM VERWALTUNGS GMBH (DE) | 2006-01-05 | — | — | US | disclosed |
| US-6274120-B1 | STABILITY; CONTRAST AGENT USED IN ULTRASOUND OR MAGNETIC RESONANCE IMAGE OF HUMAN OR ANIMAL BODY PARTS | NYCOMED IMAGING AS (NO) | 2001-08-14 | — | — | US | disclosed |
| EP-0744960-A1 | IMPROVEMENTS IN OR RELATING TO CONTRAST AGENTS | NYCOMED IMAGING AS (NO) | 1996-12-04 | — | — | EP | disclosed |
| WO-1995021631-A1 | IMPROVEMENTS IN OR RELATING TO CONTRAST AGENTS | NYCOMED IMAGING AS (NO) | 1995-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080145413-A1 | Lipids and lipid assemblies comprising transfection enhancer elements | HNRNPH3, SREBF2, PHOSPHO1 | ALDH1A1 4867/4885LMNA 446/4885PRKCA 4100/4885 |
| US-20060002991-A1 | Ph-sensitive cationic lipids, and liposomes and nanocapsules containing the same | LPAR5, LIPA, SGMS2 | ALDH1A1 4815/4885LMNA 363/4885PRKCA 296/4885 |
| US-20080306153-A1 | Lipids and lipid assemblies comprising transfection enhancer elements | SREBF1, SREBF2, ELOVL1 | ALDH1A1 3614/4885LMNA 513/4885PRKCA 2154/4885 |
| US-20090220584-A1 | Amphoteric Liposome Formulation | ANXA5, ANXA11, CLPTM1L | ALDH1A1 3919/4885LMNA 1233/4885PRKCA 4204/4885 |
| US-20220370624-A1 | LIPID COMPOSITIONS COMPRISING PEPTIDE-LIPID CONJUGATES | PHOSPHO1, LNPEP, SLC27A1 | ALDH1A1 4452/4885LMNA 659/4885PRKCA 3326/4885 |
| US-20120021042-A1 | Efficient Method For Loading Amphoteric Liposomes With Nucleic Acid Active Substances | LIPA, ANXA7, ANXA1 | ALDH1A1 1330/4885LMNA 123/4885PRKCA 3264/4885 |
| US-20220378702-A1 | PEPTIDE-LIPID CONJUGATES | GLUL, ASNS, SLC7A11 | ALDH1A1 2672/4885LMNA 3270/4885PRKCA 2861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.